Skip to main navigation Skip to search Skip to main content

Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines

Liudmyla Maksymova, Jo Van Ginderachter, Lutz Nuhn, Yannick Pilger

Research output: Contribution to journalScientific reviewpeer-review

19 Citations (Scopus)

Abstract

Among the emerging strategies for cancer theranostics, nanomedicines offer significant promise in advancing both patients’ diagnosis and treatment. In combination with nanobodies, nanomedicines can potentially enhance the precision and efficiency of drug or imaging agent delivery, addressing key limitations of current approaches, such as off-target toxicities. The development of nanomedicines will be further accelerated by the creation of smart nanoparticles, and their integration with immunotherapy. Obviously, the success of nano-immunotherapy will depend on a comprehensive understanding of the tumor microenvironment, including the complex interplay of mechanisms that drive cancer-mediated immunosuppression and immune escape. Hence, effective therapeutic targeting of the tumor microenvironment requires modulation of immune cell function, overcoming resistance mechanisms associated with stromal components or the extracellular matrix, and/or direct elimination of cancer cells. Identifying key molecules involved in cancer progression and drug resistance is, therefore, essential for developing effective therapies and diagnostic tools that can predict patient responses to treatment and monitor therapeutic outcomes. Current nanomedicines are being designed with careful consideration of factors such as the choice of carrier (e.g., biocompatibility, controlled cargo release) and targeting moiety. The unique properties of nanobodies make them an effective engineering tool to target biological molecules with high affinity and specificity. In this review, we focus on the latest applications of nanobodies for targeting various components of the tumor microenvironment for diagnostic and therapeutic purposes. We also explore the main types of nanoparticles used as a carrier for cancer immunotherapies, as well as the strategies for formulating nanoparticle-nanobody conjugates. Finally, we highlight how nanobody-nanoparticle formulations can enhance current nanomedicines.

Original languageEnglish
Article number65
Pages (from-to)65
Number of pages33
JournalMolecular Cancer
DOIs
Publication statusPublished - 4 Mar 2025

Bibliographical note

Funding Information:
L.M. is supported by a FWO-SB doctoral grant (1SH1P24N). Y.P is supported by the Graduate School of Life Sciences (GSLS) at the University of W\u00FCrzburg. L.N. acknowledges financial support by the DFG German Research Foundation (Emmy Noether program: 417278398; SFB1066: 213555243; TRR225: 326998133).

Publisher Copyright:
© The Author(s) 2025.

Keywords

  • Nanobody
  • Nanoparticle
  • Tumor microenvironment
  • Immunotherapy
  • Conjugational chemistry

Fingerprint

Dive into the research topics of 'Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines'. Together they form a unique fingerprint.

Cite this